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Abstract
Purpose Studies of SF1126, an RGDS targeted, water-
soluble prodrug of LY294002, are currently nearing com-
pletion in two adult Phase I trials. Herein, we performed a
preclinical evaluation of SF1126 as a PI-3K inhibitor for
Phase I trials in the treatment of recurrent neuroblastoma
(NB).
Methods The eVects of SF1126 on pAkt-MDM2 cell sig-
naling, proliferation, apoptosis, and migration were deter-
mined using a panel of NB cell lines, and anti-tumor
activity was determined using a xenograft model of NB.
Results SF1126 blocks MDM2 activation, IGF-1 induced
activation of Akt, and the upregulation of survivin induced
by IGF-1. It also increases sensitivity to doxorubicin in
vitro and was found to exhibit marked synergistic activity
in combination with doxorubicin. Treatment disrupts the
integrin  v3/v5-mediated organization of the actin
cytoskeleton as well as the 41/51-mediated processes
essential to metastasis. In vivo, SF1126 markedly inhibits
tumor growth in NB xenografted mice (P <0 . 0 5 ) .
Conclusions A pan PI-3 kinase inhibitor has potent anti-
tumor activity and induces apoptosis in multiple neuro-
blastoma cell lines. The observed eVects of SF1126 on
the p-Akt-MDM2-survivin axis suggest a patient selec-
tion paradigm in which NB tumors with increased pAkt-
MDM2-survivin signaling may predict response to
SF1126 alone or in combination with standard chemo-
therapy regimens that contain anthracyclines.
Keywords Pan PI3-kinase inhibitor · SF1126 · 
Neuroblastoma · MDM2 · Survivin
Introduction
Neuroblastoma (NB) is the most common extracranial solid
tumor diagnosed in children and high-risk disease carries a
dismal prognosis even with aggressive therapy [1,  2].
Nearly half of patients diagnosed with this disease have
high risk metastatic disease at the time of presentation. As a
result, the prognosis for patients with high risk NB is
extremely poor even with aggressive chemotherapy, radio-
therapy, and bone marrow transplantation [3, 4].
The PI-3 kinase-Akt pathway is a key convergent path-
way, and PI-3 kinase is a critical signaling hub downstream
of multiple growth factor receptors including TrkB,
VEGFR, PDGFR and EGFR [5–7]. It has been shown to
mediate important proliferation and survival signals, both
in tumor and endothelial cells. Activation of Akt via growth
factor receptor signaling is seen in numerous malignant
tumor cell lines and in cancer progression [8]. The IGF sys-
tem has been shown to be important in the proliferation of
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neuroblastoma and exerts its eVects through the Type 1 IGF
receptor (IGF-1R) [9–13]. Very recent research has focused
on targeting IGF-1R in neuroblastoma using a humanized
monoclonal antibody to block interaction with its ligand,
IGF-1 [13].
Increased expression of either MDM2 or survivin has
been linked to poor prognosis in a variety of tumors, but the
clinical signiWcance of elevated co-expression of these anti-
apoptotic factors has not been reported. In neuroblastoma,
increased MDM2 expression due to gene ampliWcation has
been demonstrated in several cell lines established from
tumors at relapse, and elevated MDM2 has been linked to
chemoresistance and inactivation of the p53 pathway [12].
Similarly, elevated expression of survivin in primary neuro-
blastoma tumors has been associated with increased risk of
relapse [14, 15].
Studies of the PI-3 kinase-Akt-mTOR pathway and its
eVect on the development of malignancies have led to the
use of inhibitors to alter the pathophysiology of these
malignancies, including NB. Insulin receptor substrate 1
(IRS1) normally plays a key role in transmitting signals
from IGF-1 receptors to the PI-3K/Akt pathway. In con-
trast, mTOR inhibition upregulates IGF-1R signaling
through stabilization of IRS1, leading to the paradoxical
activation of the PI-3K/Akt/mTOR pathway in NB cancer
cell lines and in NB patients treated with mTOR inhibitors,
such as rapamycin, temsirolimus and RAD001 [16,  17].
Importantly, mTOR inhibitors have also been shown to
activate Akt via the TORC2-dependent phosphorylation of
S473 site of Akt and PI-3 kinase inhibitors are known to
block the positive feedback activation of Akt [18]. This
information has driven research eVorts to develop treatment
strategies involving rational combinations of agents or sin-
gle agents that target multiple pathways in pediatric can-
cers, and underscores the need for a central targeting agent,
such as a pan-PI3-kinase inhibitor for treatment of pediatric
tumors such as NB.
One such compound, LY294002 (SF1101), has antitu-
mor and antiangiogenic activities in vivo [19]. This small
molecule also has inhibitory activity against all isoforms of
PI-3 kinase, mTOR, PLK, and PIM1 kinases (Garlich,
personal communication and AACR poster, 2010). How-
ever, the chemical, pharmacological, and toxicological data
for LY294002 prevent it from being a viable drug candi-
date. Recently, SF1126, a water-soluble, clinically viable,
tumor-targeted prodrug form of LY294002 was developed
by Semafore Pharmaceuticals; it is currently completing
two Phase I adult trials [20]. The chemical design of
SF1126 combines an integrin-targeted (primarily v3 and
51) RGDS peptide linked to LY294002 which inhibits
all classes of PI-3K (Fig. 1). We have previously described
the preclinical evaluation of PK, PD, and antitumor/antian-
giogenic activity of SF1126 [21] and we have reported that
high risk NB tumors express high levels of v3 and v5
integrins in the stromal/endothelial compartment [22].
Hence, SF1126 was designed to target the large number of
tumors expressing RGD-binding v3 integrins including
high risk NB. In a very recent paper, we also report that
SF1126 is able to reverse trastuzumab resistance in breast
cancer cells [23].
Our current data support a clinical trial of SF1126 in
recurrent/relapse neuroblastoma. We provide evidence that
SF1126 inhibits the phosphorylation of Akt and MDM2 in
NB cells and that this inhibition is dependent upon RGDS
binding to NB cells in vitro. We found that SF1126 confers
signiWcantly increased sensitivity to doxorubicin in NB cell
models, supporting its use as a combination agent. We also
found that SF1126 treatment inhibits actin-directed cyto-
skeleton reorganization and cell migration, critical to angio-
genesis and metastasis. Thus, in this work, we demonstrate
that SF1126 eVectively targets the PI-3K/Akt/MDM2 axis
in NB cells. Because elevated pAkt and MDM2 expression
are often seen at relapse in NB and are associated with che-
moresistance, the preclinical studies presented here provide
important information about SF1126 as we move toward
clinical application of this novel agent to treat NB.
Materials and methods
Cell lines and reagents
NB cell lines (SK-N-BE(2), SH-SY5Y, SK-N-MC, SH-EP1,
SK-N-AS, SK-N-F1, LA1-5S, SK-N-SH) were purchased
from the American Tissue Culture Collection (Rockville,
MD). Cell lines NB-1691, NB-EB, NB-1643, and NB-SD
were obtained directly from Sloan Kettering, St. Jude’s
CRH, CHLA or Children’s Memorial Hospital, respectively.
SK-N-F1 (a Sloan Kettering line) was obtained from B.
Spengler at Fordham University. SK-N-BE(1) cells were
provided by C.P. Reynolds (USC-CHLA) (See Supplementary
Fig. 1 Structures of SF1101/LY294002 and SF1126. SF1126 com-
bines an integrin-targeted (v3/51) RGDS peptide with SF1101/
LY294002, which inhibits all members of the PI-3 kinase family. SF1126
remains stable at acidic pH (pH < 5) and spontaneously hydrolyzes at
physiologic pH (pH 7)Cancer Chemother Pharmacol (2011) 68:325–335 327
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Data C for full description of cell lines). All cells were
maintained in RPMI + 10% FBS. NB-SD, NB-1643,
NB-1691, SK-N-BE(1), and SH-SY5Y cells contain wild-type
p53; SK-N-BE(2) and NB-EB cells contain p53 mutations.
SF1126 for these studies was supplied by Semafore Phar-
maceuticals, Inc. (Indianapolis). Antibodies speciWc for Akt,
phospho-S473-Akt, p53, MDM2, phospho-S166-MDM2
and PARP were obtained from Cell Signaling Technol-
ogy (Danvers, MA) and were used at the manufacturer’s
recommended concentrations. Vitronectin and Wbronectin
were purchased from BD Biosciences (Boston). All other
reagents were purchased from Sigma (St. Louis) unless
otherwise stated.
Proliferation assays
Cells were added to a 96-well plate at a concentration of
2–5 £ 104/100 l per well 24 h before treatment, unless
otherwise noted. Following 24–48 h treatments and vehicle
alone controls, a water-soluble tetrazolium dye solution
(WST-1: Roche; Germany) was added to each well and
allowed to incubate at 37°C for 1–2 h. Absorbance was
recorded at 450 nm with a test reference of 620 nm using a
standard 96-well plate reader, and calculations were made
after subtracting the OD of medium alone. For log-trans-
formed SF1126 concentration, nonlinear regression curve
Wt and determination of IC50, Graph Pad Prism software
was used (Graph Pad Software, Inc., La Jolla, CA). For
combined dose eVect analysis and analysis of synergism,
two methods were used. The Wrst, the isobologram method,
deWned the doses of doxorubicin and SF1126 used to pro-
duce a single-agent eVect, the IC50, and these doses were
plotted on the x and y axes. The line connecting these two
points is the line of additivity, and the response of the two
drugs used in combination at their IC50 levels were added to
this plot. This combined eVect is deWned as synergistic,
additive, or antagonistic when the point lies below, on, or
above the line of additivity, respectively. The second
method, the combination index (CI), employed a constant
ratio two drug combination, diagonal design using Calcu-
Syn software to apply the Chou–Talalay equation (Biosoft,
Ferguson, MO). Both methods are reviewed fully in refer-
ence [24].
Biochemical analyses
Cell lysates were analyzed by WB as previously described
[20]. To evaluate the eVects on Akt and MDM2 phosphory-
lation, NB cells were treated with 1, 5, 10, or 20 M
SF1126 for 60 min at 4 concentrations, or at a single
concentration over a 1 h time course. To detect apoptosis,
we examined levels of PARP and cleaved PARP following
4–24 h SF1126 treatment at 5 and 20 M. For analysis of
stimulation by IGF-1, serum-starved cells were treated for 1
and 24 h at 5 and 10 M concentrations of SF1126, in com-
bination with 100 ng/ml IGF-1 (Sigma, St. Louis, MO). To
examine the binding speciWcity of SF1126 to its RGDS tar-
gets, cells were pretreated with 50 M RGD for 0.5 h.
Actin dynamics and transwell migration assays
NB cells (SK-N-BE(2)) were seeded onto vitronectin-
coated cover slips in six well plates. Cells were treated with
25 M SF1126 for 30 min. Cortical polymerized actin
structures were visualized by Phalloidin 555 staining, and
nuclei were stained with DAPI. Stained cells were photomi-
crographed for actin polymerization using confocal micros-
copy, and cells were imaged using a Zeiss (Thornwood,
NY) LSM 510 Meta confocal microscope with a 63£ (1.4-
numerical-aperture) or 100£ (1.4-numerical-aperture) Plan-
Apochromat oil objective. All images were acquired using
Zeiss LSM 510 software and processed using Adobe Photo-
shop 7.0 as described elsewhere [25]. To assess cell migra-
tion, the bottom surfaces of transwell migration chambers
(8 M Transwell Permeable Supports, Corning) were
coated with 20 g/ml of Wbronectin for 2 h at 37°C.
SKNBE(2) cells were treated with 0, 5, or 20 M SF1126
for 0.5 h, washed, trypsinized, and added to the top cham-
bers (2.0 £ 105 cells in 200 L serum-free RPMI); the
lower chambers were Wlled with 600 L serum-free RPMI.
Following a 4-h incubation at 37°C, migrating cells were
Wxed and stained with a crystal violet solution. Nine 1 mm2
Welds were counted for each treatment, and cells were pho-
tographed at 200£ with an Olympus PX50. A Student’s
t test was used to determine levels of signiWcance.
Tumor xenograft studies
Athymic female mice (CD-1 nu/nu, 20–25 g) were used
for in vivo tumor growth inhibition studies. Mice
were obtained from the NIH/NCI repository and housed on
a 12-h light/dark cycle with food and water ad libitum
under pathogen-free conditions, according to the guidelines
of the AAALACI. Tumors derived from NB cell lines were
generated by harvesting cells from mid-log phase cultures.
Five million SKNBE(2) cells in 100 l PBS were injected
subcutaneously (s.c.) into the right Xank of each mouse.
Tumor growth was monitored twice per week for external
measurements using Vernier calipers. Tumor volume was
calculated using the formula V =( A £ B2)/2 where A and
B represent length and width of the tumor respectively.
Treatment for the antitumor eYcacy studies was initiated
when tumors in all mice ranged in size from 80 to 100 mm3.
Mice were divided randomly into two groups receiving
vehicle (acidiWed sterile water diluents for SF1126) or
SF1126. All treatment was administered s.c on the left Xank328 Cancer Chemother Pharmacol (2011) 68:325–335
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for 18 days at a dose of 50 mg/kg and at a frequency of 3
times weekly. The route of SF1126 administration and the
site of s.c. injection were chosen to most closely mimic
slow IV infusion in human Phase I trials and to avoid local-
ized concentrations near the tumor site. No toxicities were
noted in mice treated with SF1126 or vehicle. The
Student’s t test was used to compare tumor volume diVer-
ences between SF1126 treatments and vehicle-treated controls.
Results
SF1126 inhibits proliferation, induces apoptosis, 
enhances the sensitivity to doxorubicin, and reduces 
levels of pAKT and pMDM2 in NB cell lines
To assess the ability of SF1126 to inhibit cell viability, we
evaluated the eVects of SF1126 singly and in combination
with doxorubicin on NB cell survival. We determined sin-
gle-agent IC50s for twelve NB cell lines (Fig. 2a; Supple-
mentary Data A) and found that the NB-EB cell line was
the most sensitive (IC50 0.95 M) and NB-SD the least sen-
sitive (IC50 65.7 M).
When used in combination with chemotherapy, SF1126
signiWcantly increased sensitivity to pharmacologically
relevant concentrations of doxorubicin (0.02–1.0 M)
(Fig. 2b, top panel), in all three cell lines examined. By
isobologram analysis, two cell lines (SK-N-BE(1) and
SK-N-BE(2)) responded synergistically to the combined
IC50 treatment (Fig. 2b, bottom panel), while the SH-SY5Y
cell line responded in an additive manner at this dose level.
We performed analyses of synergy with Wxed-ratio dose–
response curves, using the Chou and Talalay combination
index (CI) method [24]. Using this method, the value of a
CI indicating a very strong synergism is <0.1, while a range
of 0.1–0.3 indicates a strong synergism. Our results indi-
cate a very strong to strong synergy with CI values of
0.17544, 0.11927, and 0.08385 for combined IC50s, IC70s,
and IC90s, respectively, for the SK-N-BE(1) cell line. To
ascertain the role of apoptosis, we examined the eVects of
SF1126 treatment on the cleavage product of the DNA
repair enzyme PARP. Following a 4- and 24-h treatment of
SH-N-SH and SK-N-BE(1) cells with SF1126 (Fig. 2c), we
observed a marked increase in the cleaved form of the
PARP protein (89 kD) at 24 h at both concentrations of
SF1126, indicating that SF1126 induces DNA instability
and caspase 3 induction in its promotion of apoptosis.
We next surveyed the phosphorylation status of Akt and/
or MDM2 following SF1126 treatment using immunoblot-
ting in NB cell lines SH-SY5Y, SK-N-BE(1), NB-1691,
and NB-EB and found that pAkt and constitutively elevated
pMDM2 were both reduced in a dose and time-course-
dependent manner, indicating that SF1126 blocked activation
of both Akt and its substrate MDM2. The MDM2 protein
can occur in multiple forms as a result of alternative splic-
ing; however, the roles of these alternate spliced isoforms
are not fully understood. In the current study, both the
larger (90 kD) and a smaller isoform are evident as
both unphosphorylated and phosphorylated proteins in
SH-SY5Y and NB-1691 NB cells (Fig. 2d). Notably, the
full-length phosphorylated MDM2 protein decreases with
increasing SF1126 dosage in SH-SY5Y cells, whereas
the shorter phosphorylated isoform decreases in the NB-1691
cells.
SF1126 inhibits survivin expression, MDM2 activation, 
and IGF-1-induced Akt phosphorylation 
in an RGDS-dependent manner
Members of the insulin-like growth factor (IGF) family are
important proliferative factors for NB and act through the
Akt pathway; recent evidence has shown that IGF-1 is
involved in conferring resistance to doxorubicin [11]. We
investigated the ability of SF1126 to inhibit IGF-1-driven
Akt phosphorylation in two NB cell lines, SH-SY5Y and
SK-N-BE(1) (Fig. 3a, top panel). Cells were treated with
IGF-1/SF1126 for 1 h and over a 24-h period; both treat-
ments reversed IGF-1-mediated Akt phosphorylation.
IGF-1 receptor stimulation activates Akt, upstream of
the survival signaling of MDM2 and survivin [11, 17]. We
therefore investigated IGF-driven survivin upregulation
and the inhibition of this upregulation by SF1126. SF1126
at both 5 and 20 M eVectively inhibited this upregulation
(Fig. 3a, bottom panel). To demonstrate the binding speci-
Wcity of SF1126, we pretreated cells with the RGDS pep-
tide alone and reversed the SF1126-induced inhibition of
Akt activation (Fig. 3b, top panel), conWrming that the tar-
geted activity of SF1126 is dependent on the RGD moiety
and its speciWc binding to cells.
MDM2 expression and activation are initially upregu-
lated in response to genotoxic stress. MDM2, in turn, tar-
gets p53 for ubiquitination and degradation. Thus, this
negative feedback loop inhibits p53 function following
genotoxic stress [26, 27]. The translocation of MDM2 into
the nucleus requires phosphorylation by Akt near the
nuclear translocation signal at S166/186 [5]. We investi-
gated the ability of SF1126 to inhibit this negative regula-
tion and found that it blocked the phosphorylation of
MDM2 induced by genotoxic stress, thus inhibiting its abil-
ity to downregulate p53 (Fig. 3b, bottom panel).
SF1126 disrupts the actin cytoskeleton
Many studies have shown a major role for the small
GTPase, Rac1, in the regulation of actin polymerization
and hence, integrin-directed migration [28–30]. The abilityCancer Chemother Pharmacol (2011) 68:325–335 329
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to block the migratory and invasive capacity of tumor cells
oVers an important avenue for treating patients with malig-
nant disease, and unpublished observations from our labo-
ratory as well as reports by other laboratories indicate that
PI-3 kinase activity is required for Rac1-induced cell motil-
ity [31–33]. Herein, we demonstrate marked disruption of
actin cytoskeletal Wlaments following SF1126 treatment, in
NB cells attached to vitronectin (Fig. 4a). Untreated cells
display features consistent with polarization and move-
ment, including strong F-actin staining in the extended
lamellipodia and Wlopedia (arrows). In contrast, the
SF1126-treated cells are contracted with disorganized actin
Fig. 2 SF1126 sensitizes neuroblastoma cell lines to doxorubicin
treatment, induces PARP cleavage, and blocks Akt and MDM2 activa-
tion.  a IC50s for twelve NB cell lines, taken from log transformed
SF1126 concentrations and nonlinear regression curve Wt (Supplemen-
tary Data A). b Top panel quantiWcation of cell proliferation using the
tetrazolium-based colorimetric assay, WST-1, following 24 h SF1126
and/or doxorubicin treatments. Results are compiled from 3 to 5 sepa-
rate experiments and means § SD are shown.  Black box SF1126
alone.  Grey box doxorubicin alone. Dark grey box 20 M SF1126 +
doxorubicin. *P < 0.05, **P < 0.01, ***P < 0.005.  b Bottom panel
isobologram analysis of combined IC50 doses of doxorubicin and
SF1126. Line connecting single IC50 doses is the line of additivity, and
the response of the two drugs used in combination at their IC50 levels
are indicated on these plots. The combined eVect is deWned as syner-
gistic, additive, or antagonistic when the point lies below, on, or above
the line of additivity, respectively. c SF1126 treatment of SK-N-SH
and SN-N-BE(1) cells increased levels of the PARP cleavage product.
Cells were treated for 1, 4, and 24 h at 5 and 20 M. 116 kD = full
length PARP; 89 kD = cleaved PARP. d Analysis of Akt and MDM2
inactivation following SF1126 treatment in NB cell lines. SubconXuent
neuroblastoma cell lines (a)S H - S Y 5 Y ,  ( b) SK-N-BE(1), (c)N B - E B ,
and (d) NB-1691 were incubated with 20 M SF1126 for 5, 15, 30 45
or 60 min (left) or at 1, 5, 10 or, 20 M concentrations for 60 min (right).
NT no treatment330 Cancer Chemother Pharmacol (2011) 68:325–335
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structures, and lack polarized orientations. From these data,
we can conclude that SF1126 inhibits PI3-K activity
required by the actin cytoskeletal integrity.
SF1126 inhibits Wbronectin-induced migration
Neuroblastoma is a highly metastatic tumor, a primary
cause of death in NB patients [1], and integrin-mediated
migration is a necessary step for invasion and metastasis.
Based on our Wndings that SF1126 disrupts the organization
of the actin cytoskeleton, we investigated the eVects of
SF1126 on cell migration. Fibronectin is the major extra-
cellular matrix protein, and it binds to the integrin recep-
tors, 51 and 41. The mean number of migrating cells
in the Wbronectin alone control group was 222/mm2 (§22),
while the mean number of cells migrating on Wbronectin
with 5 and 20 M SF1126, respectively, was 81 (§13) and
52 (§9) cells/mm2 ( P <0 . 0 1 )  ( F i g .4b). Thus, SF1126
Fig. 3 SF1126 inhibits 
Akt-driven signaling pathways, 
survivin expression, and 
p53-MDM2 feedback via 
RGDS-binding speciWcity. 
a Top panel SF1126 treatment 
(5 and 20 M) inhibits the 
IGF-1-induced activation of Akt 
in SH-SY5Y and SK-N-BE(1) 
NB cell lines. Cells were either 
left untreated in 10% FBS or 
serum starved (0% FBS). To 
treat cells in the presence or 
absence of 5 or 20 M SF1126, 
100 ng/ml of IGF-1 was used. 
Cells were treated for 1 h (left) 
or for 24 h (right). a Bottom 
panel SF1126 inhibits survivin 
upregulation via the PI3K/Akt 
pathway. Serum-starved 
SK-N-BE(1) cells were treated 
with 100 ng/ml IGF-1 in the 
presence or absence of SF1126 
(5 and 20 M). b Top panel 
RGD pretreatment blocks 
SF1126 inhibition. SH-SY5Y 
cells were pulsed with 50 M 
RGD for 0.5 h, washed, then 
stimulated with 100 ng/ml 
IGF-1 in the presence or absence 
of 5 M SF1126 for an addi-
tional 24 h. b Bottom panel 
SF1126 inhibits the p53-MDM2 
feedback loop. Doxorubicin 
(0.1 M) both upregulates p53 
and induces the activation of 
Mdm2; SF1126 inhibits this 
activation. SHSY5Y cells were 
treated with 0.1 M doxorubicin 
and/or SF1126 (20 M) for 4 hCancer Chemother Pharmacol (2011) 68:325–335 331
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inhibits 41/51-mediated migration, a process essential
to metastasis.
Antitumor activity of SF1126 in a NB xenograft model
With the knowledge of the inhibitory eVects of SF1126 on
SK-N-BE(2) cell proliferation, actin organization, and migra-
tion, we next tested the antitumor eYcacy of SF1126 in a
SKNBE(2) tumor xenograft model (Fig. 5). SF1126 demon-
strated robust antitumor activity, and growth rates of tumors
were signiWcantly diVerent from vehicle-treated mice (n =7 ,
P < 0.05). The mean tumor volumes between the control and
the SF1126 groups diVered signiWcantly starting at 4 days fol-
lowing treatment (802 § 466 mm3 vs. 173 § 37 mm3, respec-
tively), and these diVerences continued through the last day of
treatment (2,277 § 932 mm3 vs. 579 § 65 mm3). SF1126-
treated mice showed no evidence of toxicity, as measured by
body weight and survival relative to control animals.
Fig. 4 SF1126 blocks actin 
polymerization and alters 
cytoskeletal organization and 
cell migration. a EVect of 
SF1126 on the state of actin 
polymerization in NB cells. 
SK-N-BE(2) cells were plated 
on vitronectin and treated with 
SF1126 (25 M) for 30 min. 
Fixed cells were processed for 
confocal microscopy (see details 
in “Materials and methods”). 
Two diVerent Welds are shown, 
with and without SF1126 
treatment. b SF1126 treatment 
inhibits matrix protein 
(Wbronectin)-induced cell 
migration. SK-N-BE(2) cells 
were treated with 5 or 20 M 
SF1126 for 30 min (see details 
in “Materials and methods”). 
*P < 0.05, ***P < 0.005. FBN 
Wbronectin332 Cancer Chemother Pharmacol (2011) 68:325–335
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Discussion
There is a signiWcant need for the development of novel
eVective therapies for the treatment of NB. In the current
study, we describe the preclinical eYcacy of an RGDS-
conjugated pan-PI-3 kinase inhibitor, SF1126, in the
inhibition of NB tumor growth in vivo and the chemosensi-
tization of NB tumor cells to doxorubicin exposure in vitro.
We have deWned a signaling pathway in primary tumors
and NB cell lines which may predict responsiveness to pan
PI-3 kinase inhibition and lead to patient selection eVorts
in future Phase I trials. Unfavorable NBs usually express
TrkB, a tyrosine kinase receptor, and its ligand brain-
derived neurotrophic factor (BDNF). Our rationale for
application of pan PI-3 kinase inhibitors to NB therapeutics
is based on studies of the role of known receptor-ligand
interactions in stimulating NB growth and chemoresistance,
including but not limited to TrkB and its ligand BDGF
[2, 34,  35,  38–40] and IGF-1 [36,  37]. BDNF has been
shown to protect cells from chemotherapy, and it is known
that the phosphorylation of Akt is central to BDNF activa-
tion of TrkB signaling [35, 38, 41].
Thus, it has become increasingly apparent that the most
eVective targeted therapeutic agents are inhibitors that
block multiple kinases or an intercept point through which
multiple cell surface receptor or tyrosine kinases expert
downstream signaling eVects [42, 43]. Blocking a single
function by a speciWc receptor may fail to prevent other
receptors from providing the tumor cells with proliferative/
survival, migratory, invasive, or angiogenic signals.
Restricted spectrum inhibitors may therefore have limited
antitumor activity, and resistance will develop rapidly in
vivo. Further, the most successful tyrosine kinase inhibitor,
imatinib, exerts its antitumor activity against multiple tar-
gets, including BCR/ABL, c-KIT, and PDGFR. FDA approv-
als of two antiangiogenic agents: sorafenib (Nexavar),
in December 2005, and sunitinib (Sutent), in January 2006,
represent major landmarks for solid tumor oncology.
Sorafenib is an orally administered multi-kinase inhibi-
tor which targets RAF kinase along with VEGFR, PDGFR,
c-KIT, and other kinases [44]. This success of multi-kinase
inhibitors further supports our eVorts to target a point in
mammalian signaling through which many cell surface recep-
tors and kinases converge, PI-3 kinase.
Malignant embryonal tumors of childhood, such as NB,
are composed of highly motile cells and undergo dramatic
alterations in their actin-cytoskeletal organization that
facilitate their invasive and migratory behavior. Migration
is a process of actin reorganization and is directed by the
Rho family of small GTPases, primarily Rac1, Cdc42, and
RhoA. Polarized cells extend the membrane structures
lamellipodia and Wlopodia to become the leading cell
edge, a process requiring Rac1 and Cdc42, respectively.
RhoA, in turn, directs focal adhesion assembly, and cells
form new focal adhesions by the creation of actin stress
Wbers in the extracellular matrix [29–32], allowing them
to move forward. In neuronal cell migration, Rac1 and an
additional factor, Filamen A, are required cooperatively
to induce neurite outgrowth, and the antagonism of Cdc42
and Rac1 is known to inhibit this process [50]. Our data
demonstrate that SF1126 markedly deregulates actin Wla-
ment formation and induces a depolarized and disorga-
nized cytoskeletal actin structure. The morphological
changes ultimately resulting in migration require actin
polymerization of the lamellipodia, and SF1126 treatment
targets this polymerization. Other laboratories have also
found that blocking PI-3 kinase activation using pharma-
cological inhibitors eVectively blocks actin polymeriza-
tion [29,  45], and studies with such inhibitors have
established that PI3K/Rac1 and Cdc42 are required for
migrating neurons [46–49]. More lines of evidence dem-
onstrate that several speciWc Rac-regulated cellular func-
tions including assembly of focal complexes and
invasiveness require PI-3 kinase activity [29–31]. The
activation of Rac1 is dependent on the availability of the
guanine exchange factors Vav1 and Vav2. These, in turn,
require the PI-3K products PIP2 and PIP3 for binding to
Rac1 [50]. In this current study, inhibition of PI-3K by
SF1126 treatment likely blocked the production of PIP2
and PIP3, and ultimately, the conversion of inactive Rac1-
GDP to active Rac1-GTP.
Fig. 5 SF1126 inhibits tumor growth in a xenograft model: eVect of
SF1126 treatment in a human xenograft model. SK-N-BE(2) cells
were implanted sc in the left Xank of athymic mice as described in
“Materials and methods”. Animals were treated with 50 mg/kg
SF1126 on QOD 3 times a week by subcutaneous injection starting on
day when average tumor volume was 90–100 mm3. Tumor volumes
were measured twice a week. DiVerence in tumor volumes at days 4
and 9 after the start of therapy between control vehicle-treated mice
and SF1126-treated animals were statistically signiWcant at *P <0 . 0 5 .
The diVerences on days 14 and 17 were determined to be highly sig-
niWcant at **P < 0.01. This experiment is representative of three
experiments performedCancer Chemother Pharmacol (2011) 68:325–335 333
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Previous reports from our laboratory established that
SF1126 blocks tumor progression in vivo using multiple
adult tumor xenograft models and demonstrated that
SF1126 has both potent antiangiogenic activity and antitu-
mor activity [21]. The current Phase I clinical trial of
SF1126 in adults is at dose level 5 or 1,110 mg/m2/dose
(40 mg/kg/dose) and shows minimal toxicity. It is impor-
tant to note that the in vitro activity of SF1126 in half of the
NB cell lines surveyed is well below the highest levels
achieved in Phase I clinical trials. Moreover, pharmacoki-
netics demonstrates levels of SF1126 of 20–30 M in
plasma with evidence of pharmacodynamic inhibition of
tumor-associated pAkt in patients treated with SF1126 at
this dose [20]. In this current preclinical study, SF1126
demonstrates single-agent antitumor activity in a xenograft
model using SK-N-BE(2) NB cells. Since treatment with
SF1126 (50 mg/kg on alternate days for 3 weeks) is well
tolerated, it is likely that increasing the duration of therapy
or dose would have produced tumor regression.
Our results with SK-N-BE(2) cells which are derived
from a relapsed resistant p53 mutated tumor suggest that
the inhibitory eVects of SF1126 on tumor cell survival and
tumor growth may be mediated through p53-independent
means. Moreover, the use of this relapse NB cell line sup-
ports the potential eYcacy of SF1126 in the relapsed clini-
cal setting where p53 may be disabled. In addition to p53, a
number of other pro-apoptotic proteins are known to bind
to the N terminus of MDM2 and are regulated by levels of
MDM2 activation; these include E2F1 and p73 [51, 52].
NB relapse patients often develop p53 mutations, confer-
ring much greater resistance to standard chemotherapeutics
[12]. Here, we demonstrate that SF1126 eYcacy does not
require functional p53.
Recent work has shown that the PI-3 kinase-Akt path-
way is more signiWcantly altered in high-grade NB tumors
and tumors with poor prognostic features [7, 11]. In a lim-
ited panel of primary neuroblastoma tumor samples
(n = 18), we have utilized RT–PCR to generate data which
shows a direct correlation between high level coexpression
of both survivin and MDM2 mRNA and prognosis as deW-
ned by 3 year event free survival rates (Supplementary Data
B1, B2, B3). The combined results from our studies suggest
that the analysis of pAkt, MDM2, and survivin may serve
as surrogate biomarkers to select patients for PI-3 kinase
therapeutics. These Wndings also support the hypothesis
that agents that can downregulate both survivin expression
and MDM2 activation may provide novel approaches to the
treatment of neuroblastoma in the future. The analysis of an
expanded cohort of NB patient tumor samples will be
required to conWrm these observations.
Finally, these results indicate that SF1126 aVects NB
tumor growth by blocking tumor cell survival, proliferation,
and migration required for metastasis. SF1126 generates
its eVects via multiple signaling pathways in NB cells and
through inhibitory eVects on NB cell motility and migra-
tion. These Wndings support the evaluation of SF1126 as a
single agent or in combination with anthracyclines in neuro-
blastoma in a pediatric Phase I trial, and tumors with a highly
activated PI-3 kinase-Akt-MDM2 pathway may be most
responsive to this therapy.
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